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Abstract
Background: Membranous nephropathy (MN) is a common cause of nephrotic syndrome that may progress to
end-stage renal disease (ESRD). The formation of MN involves the in situ formation of subepithelial immune deposits
and leads to albuminuria; however, the underlying mechanism of how MN leads to ESRD remains unclear. The aim
of this study was to investigate the expression and biological functions of phosphotriesterase-related protein (PTER)
in MN.
Results: In the progression of MN, the expression of PTER increased significantly and was mainly expressed in the renal
tubular cells. Both mRNA and protein expression levels of PTER were increased in a concentration- and time-dependent
manner in the in vitro albuminuria tubular cell model. Silencing the expression of PTER by RNA interference diminished
albuminuria-induced inflammatory and pro-fibrotic cytokines production.
Conclusions: Our findings reveal that PTER may sense albuminuria in the progression of MN, induce tubular cell activation
and lead to ESRD.
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Background
Membranous nephropathy is a leading glomerular disease
and represents one of the most frequent causes of adult
idiopathic nephrotic syndrome, with up to 40-50% of pa-
tients progressing to end-stage renal disease (ESRD) [1].
The definition of MN is the presence of immune com-
plexes depositing along the glomerular basement mem-
brane (GBM) in the sub-epithelial location [2]. The
subsequent expansion of the GBM results in a membrane-
like thickening of the glomerular capillary wall and causes
the characteristic changes of albuminuria [3].
The formation of immune complex deposition may be
mediated by circulating autoantibodies which bind to
endogenous antigens in situ on the podocyte foot process,
which in turn react with glomerular endothelial cells
and GBM [4]. The M-type phospholipase A2 receptor
(PLA2R) has recently been identified as the first major
human antigenic target in adults MN [5]. In addition to
endogenous antigens, immune complexes may also be
formed by the reaction of antibodies to exogenous anti-
gens, for example cationic antigens deposit in the sub-
epithelial space, and cause membrane damage, leading
to albuminuria [6,7]. The renal functional outcome for
patients with chronic glomerulopathy can be predicted
histologically by the severity of chronic extraglomerular
damage, such as peritubular capillary loss, tubular atro-
phy and interstitial fibrosis [8]. It has been suggested
that chronic glomerular disease patients with high-
grade albuminuria are more likely to develop chronic
renal failure than patients with low-grade or no albumin-
uria [9]. In addition, urinary proteins themselves may elicit
pro-inflammatory and pro-fibrotic effects that directly
contribute to chronic tubulointerstitial damage. These
phenomena suggest the albuminuria may also exace-
rbate the severity of glomerular damage [8]. In our pre-
vious study, we found that in the process of the kidney
injury, certain intrinsic factors, such as vascular endo-
thelial cell growth factor (VEGF), thrombospondin-1
(TSP-1) and plasminogen kringle domain 5 (K5), can be
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regulated and present the protective and pathogenic
functions [10]. However, the underlying mechanism of
intrinsic factors that will induce MN injury, leading to
ESRD, remains largely unknown. Examining the differ-
ential renal mRNA and protein expression levels in the
progression of disease may help to verify specific disease
markers, and help us understand the pathogenesis of
MN.
During the course of our pilot studies on both cDNA
microarray and isobaric tag for relative and absolute
quantification (iTRAQ) analysis in MN mouse model,
we had observed both the mRNA and protein levels
of phosphotriesterase-related protein (PTER) were up-
regulated in the renal specimens of MN. PTER had been
reported its expression in the kidney proximal tubular
cells, and showed abnormal expression in injured and
cystic kidneys [11]. Accordingly, we postulated PTER
may play a crucial role in the pathophysiology of MN
and its expression might be a useful predictive biomarker
for the progression of MN.
Methods
Animal models
Animal studies were performed in accordance with insti-
tutional guidelines. Female BALB/c mice were used and
separated into experimental and control groups. Experi-
mental MN was induced by cationic bovine serum albu-
min (cBSA) as previously described [10]; however, the
control group was not injected. Once urine dipsticks
showed a marked albuminuria (++++), it was considered
full-blown MN. Mice were then euthanized, and blood,
urine and kidney samples were collected.
Human GN
The institutional review board at the National Defense
Medical Center (Taipei, Taiwan) approved the study. All
patients were over 20 years old and capable of providing
informed consent. In brief, patients with severe albumin-
uria were recruited for this study. These patients were
required to have a kidney biopsy. Cases of MN, Focal
segmental glomerulosclerosis (FSGS) and diabetic ne-
phropathy (DN) were collected to confirm the experimen-
tal findings for the MN mouse model. Kidney tissues were
obtained when patients underwent routine renal biopsies.
Immunohistochemistry
The paraformaldehyde-fixed renal tissues were embedded
in paraffin. Three micrometer sections were obtained, re-
moved paraffin from sections and followed by rehydration.
Immunohistochemical staining was performed by using the
avidin-biotin immunoperoxidase method. After quenching
the endogenous peroxidase activity and blocking with
1% BSA, the rabbit polyclonal anti-PTER antibody
(GTX102860, GeneTex, San Antonio, TX, USA) was
added and incubated at 4°C overnight. After washing, sec-
tions were incubated with biotinylated secondary antibody
(Vector laboratories, Burlingame, CA, USA) for 40 mins,
and treated with VECTASTAIN ABC (Vector laboratories)
working solution for 30 mins. The reaction was then visu-
alized by use of DAB chromogen. The developed tissues
were counterstained with hematoxylin. Sections were then
observed with an optical photomicroscope. Negative con-
trol was done by omitting the primary antibody.
Western blot analysis
After mice were euthanized, the renal cortical region
was collected for protein extraction. The protein con-
centration was determined by the BCA protein assay.
Thirty microgram of protein from each samples were
separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis. The gel was equilibrated in transfer buffer
at room temperature, and the proteins were transferred
onto polyvinylidene fluoride membranes (Immobilon-P,
Millipore, Bedford, MA, USA) for 2.5 h at 4°C in transfer
buffer. The membranes were then blocked with 2% BSA
in TBST for 1 h at 37°C, washed with TBST, and incubated
with anti-PTER (sc-107075, Santa Cruz Biotechnology,
Santa Cruz, Ca, USA) or anti-â-actin antibodies at 4°C
overnight. The next day, the membranes were then incu-
bated with appropriated secondary antibodies rabbit anti
goat for 1 h at room temperature. Bindings were visual-
ized with the Western Lightning Chemiluminescence
Reagent Plus (Perkin-Elmer Life Sciences, Boston, MA,
USA) and the density of each band was determined. All
the results were normalized for the amount of β-actin.
In vitro albuminuria model
HK-2 cell (human kidney-2) is an immortalized proximal
tubular epithelial cell line generated from a normal adult
human kidney. It was cultured in DMEM/F12 medium
supplemented with 5% FBS, 100U/ml penicillin, 100 μg/
ml streptomycin, 2 mM L-glutamine, 5 μg/ml transfer-
ring and 5 ng/ml sodium selenite, 5 pg/ml T3, 5 ng/ml
hydrocortisone, 5 pg/ml PGE1, and 10 ng/ml epidermal
growth factor. HK-2 cells were incubated at the indi-
cated concentrations of human serum albumin (HSA)
and γ-globulin in serum and growth factor-free basal
medium for 24 h and 48 h. The cells were harvested for
western blot and RT-PCR analysis.
Reverse-transcriptase polymerase chain reaction (RT-PCR)
Total RNA was extracted with Trizol reagent (Invitrogen
Corporation) from the kidney cortex. Chloroform was
added and the RNA was precipitated from the aqueous
phase with isopropanol at 4°C. RNA was reconstituted
in RNase-free water, and 18S and 28S rRNA were
checked to confirm the integrity of the RNA extracted.
Maxime RT-PCR PreMix Kit (Intron, Korea) was used for
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cDNA synthesis. Quantitative real-time PCR was per-
formed using a FastStart Universal SYBR Green Master
(Rox) reagent (Roche Diagnostics GmbH, Germany) ac-
cording to the manufacturer’s protocol, and the results were
analyzed using a LightCycler® 480 Real-Time PCR System.
The primers used in this study were as follows: PTER,
forward 5′- GGAGTTTGCTCAACTTGGCTGC-3′ and
reverse 5′- TCTTCACAGCCCTCTTCCACCA-3′; RANTES,
forward 5′- CCTGCTGCTTTGCCTACATTGC-3′ and
reverse 5′- ACACACTTGGCGGTTCTTTCGG-3′; MCP-
1, forward 5′- AGAATCACCAGCAGCAAGTGTCC-3′
and reverse 5′- CAGCAAGAGCACAAGAGGAAG-3′.
The housekeeping gene GAPDH (forward 5′- CAGCAA
GAGCACAAGAGGAAG-3′ and 5′- TGGTACATGAC
AAGGTGCGG -3′) was used as the internal standard.
siRNA Transfection
HK-2 cells (1 × 105/well) were maintained in medium in
6-well plates. Once the cells were sub-confluent, the
medium was changed to Transfection Medium (sc-36868,
Santa Cruz), Transfection Reagent (TR, sc-29528, Santa
Cruz) with PTER siRNA suspension (sc-90527, Santa
Cruz) according to manufacturer’s instructions. The
volume of TR was fixed at 4ul per the instructions.
The optimal siRNA amount was determined by HK-2
transfecting with different volumes of PTER 2 and 4ul per
well. After 24 h, cells from these different mixes were
harvested for RNA extraction. RT-PCR was used to
analyze the expression of PTER. Optimal ratio between
the volume of TR and siRNA (TR-to-siRNA) was estab-
lished based on when the knock-down efficacy of mRNA
level reached higher than 80%.
Once the optimal ratio of TR-to-siRNA was determined,
the subsequent experiments were performed as follows.
First, HK-2 cells were treated with TR containing PTER
siRNA, scramble siRNA (scRNA, sc-37007, Santa Cruz),
and TR only. After 16 hr, the culture medium was re-
placed with fresh medium containing 1 mM HSA for
24 h, and then RNA was extracted. RT-PCR was used to
analyze the gene expression levels.
Statistical analysis
All results were presented as means ± standard deviation.
Comparisons between two groups were analyzed by un-
pair t-test. Differences among multiple groups were de-
termined by the one-way analysis of variance (ANOVA)
using Tukey’s method for post hoc analysis. P < 0.05 was
considered as statistically different.
Figure 1 Differential PTER expression level in the MN mouse model. At the end of the experiment, kidney samples were collected for
histopathological examination and immunoblot analysis. Representative sections from renal tissue in MN (A, B and C) and NC (D, E and F)
groups were examined with PTER immunohistochemical stain, original magnifications: 100× (A and D), 200× (B and E) and 400× (C and F). In
addition, (G) represented negative controls staining without primary antibody in NC section, 400X. Total protein lysate was extracted from the
renal cortical region and separated in 10% SDS page by electrophoresis, and further blotting by anti-PTER and β-actin antibodies (H). The bar
chart represents the semi-quantification level of the expression density (I) (PTER/β-actin). *, p < 0.05.
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Results
Differential renal tubular PTER expression in MN
To confirm the up-regulation of PTER protein level in MN,
the renal cortical proteins were extracted and analyzed by
western blotting. When compared to the control group, the
expression of PTER protein was significantly increased in
the MN group. Immunohistochemistry stain was also used
to analyze the renal distribution pattern and expression
level of PTER in MN. PTER protein was expressed in the
renal tubular cells in the control group and increased mark-
edly in the full-blown MN, as represented by the marked
albuminuria (Figure 1). PTER also strongly expressed in the
human MN, DN, FSGS cases, which all presented with
marked albuminuria (Table 1 & Figure 2). Table 1 showed
all clinical cases’ basic data and tubular expression of PTER.
Regarding intensity of PTER in renal tubules, histological
pictures were evaluated by two separated pathologists, and
scored by grade from+ to ++++. The average score was
shown in Table 1.
Increased PTER mRNA and protein expression in an
in vitro albuminuria model
In order to validate the role of PTER in the pathogenesis
of albuminuria, a well-established in vitro albuminuria
cell model was created by treating immortalized prox-
imal tubular epithelial cell line HK-2 with HSA. HK-2
cells incubated with various concentrations of HSA (ran-
ging from 0.1-1 mM) for 48 h did not show significant
alteration in the cell viability (data not shown). Treatment
Table 1 Clinical data and tubular expression of PTER for
patients with MN, FSGS and DN
Case MN FSGS DN
1 2 3 4
Age(y/o) 80 85 61 50 34 47
Gender M M M M M F
Up/Ucr 4.1 19.2 3.2 18.9 2.2 2.5
Scr(mg/dl) 0.7 3.5 0.8 1.0 1.0 0.8
Salb(g/dl) 1.8 1.9 2.6 1.8 2.2 2.8
Intensity of PTER in renal tubules + +++ ++ ++ ++ ++
Abbreviations: MN membranous nephropathy, FSGS focal segmental
glomerulosclerosis, DN diabetic nephropathy, PTER phosphotriesterase-related
protein, y/o years old, M male, F female, Up urine protein, Ucr urine creatinine,
Scr serum creatinine, Salb serum albumin.
Figure 2 Expression of PTER in human clinical specimens. Representative sections from clinical kidney tissue specimens of MN (A-D), FSGS
(E) and DN (F) patients were performed with PTER immunohistochemical stain (arrows indicate glomerulus), original magnifications: 100×. The
clinical data are presented in Table 1.
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with increased concentrations of HSA had increased the
PTER mRNA expression level gradually (Figure 3A). In-
flammatory mediators (MCP-1 and RANTES) and pro-
fibrotic cytokine (TGF-β1) mRNA had been reported with
overexpression in tubular epithelial cells of patients with
severe proteinuria and progressive MN [12]. In the
in vitro albuminuria model, the mRNA expression levels
of MCP-1, RANTES and TGF-β1 also increased, repre-
senting tubular cell activation (Figure 3B-D). As expected,
HSA increased PTER protein expression in time- and
dose- dependent manners (Figure 4A-C). However, treat-
ment with 0.03 mM of γ-globulin did not influence PTER
protein expression (Figure 4D and E). HK-2 cells were also
treated with different levels of glucose and the relative
osmolality control mannitol, to further examine the influ-
ence of high glucose in PTER protein expression. Unlike
HSA treatment, increased glucose level in the culture
medium did not affect the PTER protein expression in 24
and 48 h (Figure 5). These data supported our hypothesis
that PTER may be specifically participated in response to
albuminuria.
Suppressed PTER expression abrogated albuminuria-
induced renal tubular cell activation
Specific PTER siRNA was applied to analyze the bio-
logical effects of PTER expression in the pathogenesis of
albuminuria. Silencing the expression of PTER diminished
HSA induced MCP-1, RANTES and TGF-β1 expression
levels in HK-2 cell (Figure 6). These data suggest PTER
protein participates in the albuminuria-mediated proximal
tubular cell activation.
Discussion
In this study, we identified PTER as being involved in
the progression of MN from the animal model and clin-
ical cases. The up-regulation of PTER in the tubular
cells may be represented as a sensor protein in response
to the albuminuria in the progression of MN. Further-
more, protein overload-induced PTER expression regulates
tubular cell activation in the chemokine and pro-fibrotic
cytokine expression. These findings also imply that PTER
may present a detrimental role in the scenario from
MN to ESRD.
Microbial phosphotriesterases are a group of zinc
metalloenzymes that catalyze the hydrolysis of one class
of highly toxic synthetic compounds known as organo-
phosphates [13]. Originally, the phosphotriesterase was
found in the bacteria Pseudomonas diminuta and Flavo-
bacterium sp [14]. Subsequently, PTER was also isolated
and identified in mice and rats. The PTER mRNA is espe-
cially expressed in the kidney proximal tubular cells and
the expression begins post-natally and lasts to adulthood
Figure 3 Increased PTER, MCP-1, RANTES and TGF-β1 expression in an in vitro albuminuria model. HK-2 cells were treated with 1 mM
HSA, and the total cellular RNA was isolated at different time points as described in Methods, and subjected to real-time PCR analysis for PTER
(A), MCP-1 (B), RANTES (C) and TGF-β1 (D) expression. The mRNA expression levels were normalized to GAPDH, and the results are presented as
mean ± SD. a, p < 0.05 in comparison with the control group.
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[11,15]. From the differential cDNA library screening in be-
tween normal and cystic kidneys of the C57BL/6 J-cpk
mouse, PTER was significantly under-expressed in cystic
kidneys [11]. The expression of PTER increased in both
mRNA and protein levels in the progression of MN and
was mainly expressed in the proximal tubular cells (Table 1,
Figures 1 and 2). Furthermore, we also suggest that PTER
is expressed in FSGS and DN with albuminuria. Taken
together, these results suggest PTER may also be involved
in some kidney diseases, including MN.
The main manifestation of MN is the presentation of
immune complexes deposition along the GBM in the
sub-epithelial location, which leads to glomerular capil-
lary wall damage, resulting in albuminuria. In normal
conditions, trace amounts of proteins can escape into
the glomerular filtrate and be reabsorbed in the apical
pore of proximal tubular cells. The process is mediated
by the brush border-enriched endocytic receptors mega-
lin and cubilin through ligand-receptor complex formed
endocytic vesicles [16-18]. The presence of excessive
amounts of urinary proteins may elicit the pathogenesis
of chronic tubulointerstitial damage. Urinary protein ex-
cretion rate has also been considered as a predictor of
ESRD in progressive kidney injury [19]. It has been sug-
gested that megalin may regulate the abnormal protein
exposure of tubular cells, activate the transcription factor,
and facilitate proinflammatory signaling [20]. However,
because megalin can bind the trace amounts of pro-
teins without inducing tubular cell activation; other
mechanisms may also be involved in sensing albumin-
uria. In addition, it has been reported that human γ-
globulin (0.03 mM) can be absorbed by opossum kidney
epithelial cells through a megalin/cubilin-mediated,
clathrin-dependent endocytosis [21]. In the current
study, treatment γ-globulin did not induce the PTER
expression. This may also suggest that PTER can sense
albuminuria, at least in part, but not involved in the
megalin-mediated mechanism.
In vitro protein overload cell models have been
widely used to assess the specific mechanisms linking
to excess exposure to proteins [22-24]. In this study,
the expression of PTER increased in a concentration-
and time-dependent manner in the albumin overload
Figure 4 PTER protein was specifically expressed in response to
HSA-induced in vitro albuminuria model. Immunoblot analysis for
the expression of PTER at 24 and 48 h in different concentrations of
HSA (0.1, 0.5 and 1 mM)-treated HK-2 cells were examined (A). Data
represent one out of three experiments. The relative PTER protein
levels at 24 (B) and 48 h (C) were then normalized to β-actin and
the results were presented as mean ± SD. a, p < 0.05 in comparison
with the control group. The expression of PTER at 24 and 48 h in
0.03 mM γ-globulin-treated HK-2 cells were examined (D). The PTER
protein expression levels were then normalized to β-actin and the results
were presented as mean± SD (E). N.S, No significant difference was found.
Figure 5 PTER protein level was not affected by in vitro
hyperglycemia model. Immunoblot analysis for the expression of
PTER at 24 h and 48 h in different concentrations of D-glucose (A)
and D-mannitol (30, 40, 50 and 100 mM) were also examined (B).
Data represent one out of three experiments.
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in vitro cell model (Figures 3 and 4). It is of note that
the PTER expression level was not affected in the ex-
cess of glucose or γ-globulin, suggesting its specificity
in response to albumin-overload stimuli (Figure 5).
The PTER expression pattern is also similar to the
expression of MCP-1, RANTES and TGF-β1 (Figure 3);
silencing PTER by specific siRNA diminished the ex-
pression (Figure 6). These suggest PTER may, at least
in part, participate in modulating chemokine and pro-
fibrotic cytokine production in mediating renal injury in
Figure 6 Silencing PTER expression diminished albuminuria-induced renal tubular cell activation. The PTER siRNA (siRNA), negative
control RNA (scRNA) and transfection reagent alone (TR) transfected HK-2 cells were treated with 1 mM HSA for 24 h for real-time PCR analysis.
The mRNA expression levels of PTER (A), MCP-1 (B), RANTES (C) and TGF-β1 (D) were normalized to GAPDH, and the results are presented as
mean ± SD. Total cell protein was extracted at the indicated time points and subjected to analysis of the PTER protein expression levels (E). The
relative expression levels were normalized to β-actin and the results were presented as mean ± SD (F). a, p < 0.05 in comparison with the control
group; b, p < 0.05 in comparison with the HSA group.
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response to albuminuria. However, the exact mechanism
by which PTER mediates renal injury in response to urin-
ary protein requires further study.
Conclusions
Overall, the findings of this study showed that proximal
tubular cells expressing PTER can sense the albumin
overload-induced injury and regulate the tubular cell
activation. Accordingly, future studies are necessary to
discern the detailed mechanisms of PTER in sensing
urinary albumin.
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